Rimas V Lukas1,2,3, Csaba Juhász4,5, Derek A Wainwright6,7,8, Charles David James6,7,8, Eugene Kennedy9, Roger Stupp10,6,7,8, Maciej S Lesniak6,7,8. 1. Department of Neurology, Northwestern University, 710 N. Lake Shore Drive, Abbott Hall 1114, Chicago, IL, 60611, USA. rimas.lukas@nm.org. 2. Lurie Cancer Center, Northwestern University, Chicago, USA. rimas.lukas@nm.org. 3. Lou & Jean Malnati Brain Tumor Institute, Northwestern University, Chicago, USA. rimas.lukas@nm.org. 4. Neurology, and Neurosurgery, Department of Pediatrics, Wayne State University, Detroit, USA. 5. Karmanos Cancer Institute, Wayne State University, Detroit, USA. 6. Department of Neurosurgery, Northwestern University, Chicago, USA. 7. Lurie Cancer Center, Northwestern University, Chicago, USA. 8. Lou & Jean Malnati Brain Tumor Institute, Northwestern University, Chicago, USA. 9. NewLink Genetics, Ames, USA. 10. Department of Neurology, Northwestern University, 710 N. Lake Shore Drive, Abbott Hall 1114, Chicago, IL, 60611, USA.
Abstract
INTRODUCTION: Glioblastoma (GBM) is the most frequent and aggressive primary tumor of the central nervous system, accounting for over 50% of all primary malignant gliomas arising in the adult brain. Even after surgical resection, adjuvant radiotherapy (RT) and temozolomide (TMZ) chemotherapy, as well as tumor-treating fields, the median survival is only 15-20 months. We have identified a pathogenic mechanism that contributes to the tumor-induced immunosuppression in the form of increased indoleamine 2,3 dioxygenase 1 (IDO1) expression; an enzyme that metabolizes the essential amino acid, tryptophan (Trp), into kynurenine (Kyn). However, real-time measurements of IDO1 activity has yet to become mainstream in clinical protocols for assessing IDO1 activity in GBM patients. METHODS: Pre-treatment and on-treatment α-[11C]-methyl-L-Trp (AMT) positron emission tomography (PET) with co-registered MRI was performed on patients with recurrent GBM treated with the IDO1 pathway inhibitor indoximod (D1-MT) and TMZ. RESULTS: Regional intratumoral variability of AMT within enhancing and non-enhancing tumor was noted at baseline. On treatment imaging revealed decreased regional uptake suggesting IDO1 pathway modulation with treatment. CONCLUSIONS: Here, we have validated the ability to use PET of the Trp probe, AMT, for use in visualizing and quantifying intratumoral Trp uptake in GBM patients treated with an IDO1 pathway inhibitor. These data serve as rationale to utilize AMT-PET imaging in the future evaluation of GBM patients treated with IDO1 enzyme inhibitors.
INTRODUCTION: Glioblastoma (GBM) is the most frequent and aggressive primary tumor of the central nervous system, accounting for over 50% of all primary malignant gliomas arising in the adult brain. Even after surgical resection, adjuvant radiotherapy (RT) and temozolomide (TMZ) chemotherapy, as well as tumor-treating fields, the median survival is only 15-20 months. We have identified a pathogenic mechanism that contributes to the tumor-induced immunosuppression in the form of increased indoleamine 2,3 dioxygenase 1 (IDO1) expression; an enzyme that metabolizes the essential amino acid, tryptophan (Trp), into kynurenine (Kyn). However, real-time measurements of IDO1 activity has yet to become mainstream in clinical protocols for assessing IDO1 activity in GBM patients. METHODS: Pre-treatment and on-treatment α-[11C]-methyl-L-Trp (AMT) positron emission tomography (PET) with co-registered MRI was performed on patients with recurrent GBM treated with the IDO1 pathway inhibitor indoximod (D1-MT) and TMZ. RESULTS: Regional intratumoral variability of AMT within enhancing and non-enhancing tumor was noted at baseline. On treatment imaging revealed decreased regional uptake suggesting IDO1 pathway modulation with treatment. CONCLUSIONS: Here, we have validated the ability to use PET of the Trp probe, AMT, for use in visualizing and quantifying intratumoral Trp uptake in GBM patients treated with an IDO1 pathway inhibitor. These data serve as rationale to utilize AMT-PET imaging in the future evaluation of GBM patients treated with IDO1 enzyme inhibitors.
Entities:
Keywords:
1-MT; AMT; Biomarker; Glioblastoma; IDO; Indoximod; PET
Authors: David Mattes; David R Haynor; Hubert Vesselle; Thomas K Lewellen; William Eubank Journal: IEEE Trans Med Imaging Date: 2003-01 Impact factor: 10.048
Authors: Jaswir Basran; Sara A Rafice; Nishma Chauhan; Igor Efimov; Myles R Cheesman; Lila Ghamsari; Emma Lloyd Raven Journal: Biochemistry Date: 2008-03-28 Impact factor: 3.162
Authors: Farhad Forouhar; J L Ross Anderson; Christopher G Mowat; Sergey M Vorobiev; Arif Hussain; Mariam Abashidze; Chiara Bruckmann; Sarah J Thackray; Jayaraman Seetharaman; Todd Tucker; Rong Xiao; Li-Chung Ma; Li Zhao; Thomas B Acton; Gaetano T Montelione; Stephen K Chapman; Liang Tong Journal: Proc Natl Acad Sci U S A Date: 2006-12-29 Impact factor: 11.205
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Csaba Juhász; Diane C Chugani; Otto Muzik; Dafang Wu; Andrew E Sloan; Geoffrey Barger; Craig Watson; Aashit K Shah; Sandeep Sood; Eser L Ergun; Tom J Mangner; Pulak K Chakraborty; William J Kupsky; Harry T Chugani Journal: J Cereb Blood Flow Metab Date: 2006-03 Impact factor: 6.200
Authors: Carlos E A Batista; Csaba Juhász; Otto Muzik; William J Kupsky; Geoffrey Barger; Harry T Chugani; Sandeep Mittal; Sandeep Sood; Pulak K Chakraborty; Diane C Chugani Journal: Mol Imaging Biol Date: 2009-05-12 Impact factor: 3.488
Authors: Peter Wierstra; Gerwin Sandker; Erik Aarntzen; Martin Gotthardt; Gosse Adema; Johan Bussink; René Raavé; Sandra Heskamp Journal: EJNMMI Radiopharm Chem Date: 2019-11-06
Authors: Silvia Valtorta; Daniela Salvatore; Paolo Rainone; Sara Belloli; Gloria Bertoli; Rosa Maria Moresco Journal: Int J Mol Sci Date: 2020-08-06 Impact factor: 5.923